China National Medicines Corporation Ltd.

SHSE:600511 Rapport sur les actions

Capitalisation boursière : CN¥25.9b

China National Medicines Croissance future

Future contrôle des critères 1/6

China National Medicines devrait augmenter ses bénéfices et son chiffre d'affaires de 9.1% et de 8.9% par an respectivement. Le BPA devrait croître de de 9.5% par an. Le rendement des capitaux propres devrait être 12.7% dans 3 ans.

Informations clés

9.1%

Taux de croissance des bénéfices

9.5%

Taux de croissance du BPA

Healthcare croissance des bénéfices23.0%
Taux de croissance des recettes8.9%
Rendement futur des capitaux propres12.7%
Couverture par les analystes

Low

Dernière mise à jour12 Nov 2024

Mises à jour récentes de la croissance future

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Recent updates

We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

Nov 12
We Think China National Medicines (SHSE:600511) Can Manage Its Debt With Ease

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28
Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24
China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07
China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05
Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10
Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28
China National Medicines (SHSE:600511) Could Easily Take On More Debt

Prévisions de croissance des bénéfices et des revenus

SHSE:600511 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/202662,5162,688N/A2,8712
12/31/202557,7642,458N/A2,2083
12/31/202452,8102,293N/A1,9022
9/30/202451,1952,1651,5401,688N/A
6/30/202450,3122,1621,6881,827N/A
3/31/202450,5922,1912,0082,151N/A
12/31/202349,6962,1462,5822,727N/A
9/30/202347,4861,9952,4662,602N/A
6/30/202347,6322,0862,0402,194N/A
3/31/202345,6652,0052,4292,560N/A
12/31/202245,4991,9642,2652,395N/A
9/30/202246,7191,8841,3361,460N/A
6/30/202246,3991,8501,0811,185N/A
3/31/202247,1851,8301,7461,851N/A
12/31/202146,4691,7541,8621,957N/A
9/30/202145,5591,6801,0851,170N/A
6/30/202144,9231,5291,1291,197N/A
3/31/202142,5121,4491,1871,247N/A
12/31/202040,3791,3831,2331,302N/A
9/30/202041,0461,5371,0581,125N/A
6/30/202041,1531,4691,9221,997N/A
3/31/202042,8051,5491,3991,477N/A
12/31/201944,6441,6041,6901,776N/A
9/30/201942,6731,5251,0371,139N/A
6/30/201940,9911,5231,0241,159N/A
3/31/201939,6591,436-33103N/A
12/31/201838,7401,404849982N/A
9/30/201837,9941,2562,4572,576N/A
6/30/201837,4521,224N/A2,058N/A
3/31/201836,6531,163N/A1,424N/A
12/31/201736,2851,141N/A1,074N/A
9/30/201736,0721,060N/A63N/A
6/30/201735,5401,044N/A-85N/A
3/31/201740,1031,101N/A488N/A
12/31/201634,611990N/A1,043N/A
9/30/201628,613887N/A461N/A
6/30/201622,813752N/A716N/A
3/31/201612,408527N/A445N/A
12/31/201512,078513N/A440N/A
9/30/201512,065499N/A307N/A
6/30/201511,894499N/A424N/A
3/31/201511,773490N/A394N/A
12/31/201411,538483N/A219N/A
9/30/201411,177465N/A338N/A
6/30/201410,824457N/A240N/A
3/31/201410,408431N/A204N/A
12/31/201310,081412N/A186N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de 600511 ( 9.1% par an) est supérieure au taux d'épargne ( 2.8% ).

Bénéfices vs marché: Les bénéfices de 600511 ( 9.1% par an) devraient croître plus lentement que le marché CN ( 26.1% par an).

Croissance élevée des bénéfices: Les bénéfices de 600511 devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 600511 ( 8.9% par an) devrait croître plus lentement que le marché de CN ( 13.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 600511 ( 8.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 600511 devrait être faible dans 3 ans ( 12.7 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y